Inducing Targeted Protein Degradation – From Chemical Biology to Drug Discovery and Clinical Applications

Philipp M. Cromm studied Chemistry at the Technical University Munich where he worked in the group of Horst Kessler. For his master's thesis he spent time with David J. Craik at the Institute for Molecular Bioscience and received his PhD under guidance of Herbert Waldmann at the Max-Planck-Institute for Molecular Physiology. Thereafter, he carried out postdoctoral studies in the group of Craig Crews at Yale University working on targeted protein degradation. In 2018 Philipp joined Bayer AG as a Medicinal Chemist.

Targeted Protein Degradation - The Story So Far Cellular Principles of Targeted Protein Degradation E3 Ubiquitin Ligases as Molecular Machines and Platforms for Drug Development A Structural and Biophysical Perspective of Degrader Activity through Ternary Complex Formation Computational Modeling of PROTAC Ternary Complexes and Linker Design Molecular Glue Degraders: From Serendipity to Hunting and Design Targeted Protein Degradation as a Therapeutic Strategy in Neurodegenerative Diseases Insights and Future Perspectives of Covalent Protein Degraders Extending the Degradation Toolkit - mRNA targeting as Alternative Means to Affect Protein Levels The Future of Heterobifunctional Compounds: PROTACs and Beyond Destruction with a Purpose: Targeted Protein Degradation in Drug Discovery Taming the Beast: How to Optimize DMPK-PD Properties of Oral Degraders PROTAC® Protein Degraders: Bridging the Divide from Chemical Biology Tools to Clinical Candidates